The Effective and Safety of Thalidomide in TI
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03184844|
Recruitment Status : Unknown
Verified June 2017 by Xiao-Lin Yin, 303rd Hospital of the People's Liberation Army.
Recruitment status was: Recruiting
First Posted : June 14, 2017
Last Update Posted : June 14, 2017
|Condition or disease||Intervention/treatment||Phase|
|Thalassemia||Drug: Thalidomide||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Multi-center Clinical Trials of Thalidomide in TI|
|Actual Study Start Date :||May 2, 2017|
|Estimated Primary Completion Date :||February 2, 2019|
|Estimated Study Completion Date :||May 2, 2019|
Experimental: thalidomide thalassemia
thalidomide:50mg/d p.o at bedtime
Other Name: fǎn yìng tíng
- The Effective Rate of Patients [ Time Frame: 24 months ]All participants will complete the treatment for 24 months, the hemoglobin value will be observed during the treatment,the value increased more than 20g/L defined as the marked effect,increased to 10~20g/L defined as effective, otherwise invalid.
- The Marked Improvement Rate of Patients [ Time Frame: 24 months ]The highest hemoglobin value will be observed,the value increased more than 20g/L defined as the marked effect,increased to 10~20g/L defined as effective, otherwise invalid.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03184844
|Contact: Liu Ch xu, President||0771 email@example.com|
|NO.3 Hospital of the Chinese People's Liberation Army||Recruiting|
|Nanjing, Guangxi, China, 530021|
|Contact: Li L Zhu, Assistant 0771 2870303 firstname.lastname@example.org|
|Study Director:||Yin X Lin, director||NO.3 Hospital of the Chinese People's Liberation Army|